Company profile
MYND Life Sciences Inc.
OTC: MYNDF · Healthcare · Biotechnology
Canadian filerHQ Kelowna, BCReports USD
#1065 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 23
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, market scale · ↓ balance-sheet leverage, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.1M
Employees
—
as of 2026-08-26
Market cap
$657.8k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$68.9k93.0k CAD2023
Net income-$1.1M-1.5M CAD2023
Operating income-$1.4M-1.8M CAD2023
Total assets$575.0k797.5k CAD2023
Liabilities$4.2M5.8M CAD2023
Equity-$3.6M-5.0M CAD2023
Revenue trend
FY2019 – FY2023 · USD
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is MYND Life Sciences Inc.’s revenue?
MYND Life Sciences Inc. booked $68.9k in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -1632.3% net margin.
Peers · Healthcare
Exlites Holdings International, Inc.54DeXoZymes, Inc.24DOncotelic Therapeutics, Inc.46DVivos Inc.48DNeutra Corp.——Aquarius Surgical Technologies Inc.——Key facts
CEOWilfred A. Jefferies
SectorHealthcare
IndustryBiotechnology
HeadquartersKelowna, BC
ExchangeOTC: MYNDF
Employees—
IPO date2021-09-22
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.